Dr
Jonathan
Atkinson

Partner & Patent Attorney

Leeds Office

Chemistry

Telephone. +44(0) 113 233 0100
Mobile. +44(0) 776 665 6290
Email. [email protected]

Experience

Jonathan's practice involves providing commercially-focussed advice on patent origination, patent strategy and portfolio management, licensing and due diligence, prosecuting and defending European patent oppositions, and conducting patent litigation in the UK and Europe.

His practice draws in this variety of experience and extends to a wide range of chemical and pharmaceutical subject matter. Jonathan's practice in the pharmaceutical area has covered both contentious and non-contentious issues and he has provided external consultancy services to a number of large pharmaceutical companies over the last 20 years.

His practice involves providing commercially focused advice to C-suite business leaders, R&D groups, and public institutions on all aspects of patent strategy and portfolio management. This includes obtaining and defending patent rights, providing opinions on freedom to operate where third party intellectual property rights exist, conducting due diligence to support corporate acquisition and licensing deals, challenging third party patent rights and pan-European pharmaceutical litigation.

Jonathan has worked on a number of high profile pharmaceutical matters including working as part of the patent procurement team for Viagra™; prosecution and litigation surrounding Augmentin™, Ritalin™ and Fosrenol™; opposition/appeal work on Zithromax™, Perindopril and Sovaldi™ and due diligence work to support acquisitions (eg New River Pharmaceuticals and Renovo, and IPO's (eg Redx and NuCana plc), and private equity investment funding (eg OriBiotech).

In the non-pharmaceutical area, he has been responsible for filing all of the foundation patents for graphene on behalf of Manchester University's two Nobel Prize winners Geim and Novoselov.

Jonathan's clients include large and small companies, universities and government organisations.

Qualifications

Patent Attorney

Europe


BA

Chemistry (Oxon)

MA

Chemistry (Oxon)

POSTGRADUATE DIPLOMA OR CERTIFICATE

Cert in IP Law Queen Mary, London

POSTGRADUATE DIPLOMA OR CERTIFICATE

C. Chem, FRSC

OTHER

D.Phil. (Oxon)

Publications

IAM Patent 1000 2019

View publication online

Related News

From Theoretical Proposals to Commercial Reality: The Rise of Innovation and Patent Filings in Quantum Computing

The possibility of quantum computing was first seriously proposed in the early 1980s and is widely regarded as having enormous potential to deliver a step change in the complexity of …

Read article
Event - 3rd February 2023

The European Patent Office are running an inspiring collaborative art competition for children

To celebrate the 50th anniversary of the signing of the European Patent Convention, The European Patent Office (EPO) is running a collaborative art competition for primary schools on the topic …

Event details
Event - 8th-9th February 2023

5th Annual Microbiome & Probiotic Conference 2023

The 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference will take place in San Diego on the 8th-9th of February. This conference will enable you to learn about microbial …

Event details
Event - 17th January 2023

CIPA Webinar: Enhancing Diversity in the Patent Profession How Can I Help

CIPA hosted a webinar to discuss ‘Enhancing diversity in the patent profession.’ Date Tuesday 17 January, 2023 Time 12.30pm – 1.30pm (GMT) Equity, diversity and inclusion has been in the …

Event details

LiDAR: A Significant Support Technology at CES

When visiting CES’ one thing that struck me was the number of companies demonstrating LiDAR technology. LiDAR has been around since the 1960s and was originally developed for aerospace use, …

Read article

Healthcare and Climate Change

Can we find a balance between intellectual property rights and public health needs when tackling the climate crisis? “The world faces a critical juncture. A health-centred, aligned response to the …

Read article

Navigating the CRISPR IP confusion

It is just over 10 years since the Science publication of Jinek et al. showed for the first time that DNA cleavage could be achieved in vitro with a Cas9 …

Read article

CRISPR Edited T cells win the TvT Battle

T-cells which have been modified using CRISPR base editing technology have been successfully used to treat T-cell acute lymphoblastic leukaemia for the first time {1}. A 13 year old patient …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.